4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
An Integrated European ‘Flagship’ Program Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st Century (EU-ToxRisk)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2021,
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Voir le projet
43
Participants partenaires
TERMINÉ
Production and characterization of endocrine cells derived from human pancreas organoids for the cell-based therapy of type 1 diabetes (LSFM4LIFE)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Self-renew and multilineage potential characterize stem cells. We have recently described that pancreas progenitor cells extracted from adult donors can be expanded long-term in vitro into 3D structures, which we have termed organoids. Pancreas organoids reproduce in vitro all the features of pancreas ductal epithelia, and have a limitless expansion potential. Thus, pancreas organoids promise t ...
Voir le projet
7
Participants partenaires
TERMINÉ
Hepatic and Cardiac Toxicity Systems modelling (HECATOS)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
HeCaToS aims at developing integrative in silico tools for predicting human liver and heart toxicity. The objective is to develop an integrated modeling framework, by combining advances in computational chemistry and systems toxicology, for modelling toxic perturbations in liver and heart across multiple scales. This framework will include vertical integrations of representations from drug(metabol ...
Voir le projet
14
Participants partenaires
TERMINÉ
The Body-on-a-Chip (BoC) (BOC)
Date du début: 1 juin 2012, Date de fin: 31 mai 2015,
High attrition and failures rates in pharmaceutical and biotechnological drug development require a paradigm change towards more physiological human cell-based assays at an early time point in the process. The central idea of this proposal is to develop a versatile and reconfigurable pharmaceutical screening technology platform that relies on organotypic three-dimensional spherical microtissues. T ...
Voir le projet